Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by G1945Von Jun 24, 2022 5:47am
145 Views
Post# 34779428

RE:RE:Insider buying today :

RE:RE:Insider buying today :
Mole101 wrote: There is the volume for today ..
Recent filings 
2022-06-2308:44
 
2022-06-23
$PMN Kirwin, Patrick D.
4 - Director of Issuer
Holder: Patrick D Kirwin Professional Corporation (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$23,000 
+200,000vol 
$0.115each
1,339,900  
2022-06-2308:40
 
2022-06-23
$PMN Williams, Eugene Warren
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$49,450 
+500,000vol 
$0.0989each
8,503,816  



[/quote]

M101, stated, "There is the volume for today ."

Why downplay the volume if that is what you are doing.

Total share volume for 2 days (22nd & 23rd) total to 2,280,600.
Less the 700,000 shares transacted by 2 board members  = 1,580,600.

Nothing wrong with that volume.


G1945V
<< Previous
Bullboard Posts
Next >>